Clinical aspects of intratumoral gene therapy

Emmanuel T. Akporiaye, Evan M Hersh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

One of the major obstacles to the development of gene therapy for cancer is our inability to deliver genes to all targets within the body. Thus, effective methodology does not exist to deliver a gene intravenously with the expectation that it will selectively localize within the target tumor, will not localize in other tissues and will be expressed efficiently. While one can take advantage of tissue-specific promoters to activate the gene only in a given target tissue, only a small fraction of the vector will be taken up in the target tissue and expressed. Consequently, since accessible local or regional tumor masses are a major problem in many cancers, there has been a strong emphasis on clinical trials in intratumoral and peritumoral gene delivery.

Original languageEnglish (US)
Pages (from-to)443-453
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume1
Issue number4
StatePublished - 1999

Fingerprint

Genetic Therapy
Genes
Neoplasms
Clinical Trials

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Clinical aspects of intratumoral gene therapy. / Akporiaye, Emmanuel T.; Hersh, Evan M.

In: Current Opinion in Molecular Therapeutics, Vol. 1, No. 4, 1999, p. 443-453.

Research output: Contribution to journalArticle

Akporiaye, Emmanuel T. ; Hersh, Evan M. / Clinical aspects of intratumoral gene therapy. In: Current Opinion in Molecular Therapeutics. 1999 ; Vol. 1, No. 4. pp. 443-453.
@article{1a05e89fb8e048d08a37d8106331ec08,
title = "Clinical aspects of intratumoral gene therapy",
abstract = "One of the major obstacles to the development of gene therapy for cancer is our inability to deliver genes to all targets within the body. Thus, effective methodology does not exist to deliver a gene intravenously with the expectation that it will selectively localize within the target tumor, will not localize in other tissues and will be expressed efficiently. While one can take advantage of tissue-specific promoters to activate the gene only in a given target tissue, only a small fraction of the vector will be taken up in the target tissue and expressed. Consequently, since accessible local or regional tumor masses are a major problem in many cancers, there has been a strong emphasis on clinical trials in intratumoral and peritumoral gene delivery.",
author = "Akporiaye, {Emmanuel T.} and Hersh, {Evan M}",
year = "1999",
language = "English (US)",
volume = "1",
pages = "443--453",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - Clinical aspects of intratumoral gene therapy

AU - Akporiaye, Emmanuel T.

AU - Hersh, Evan M

PY - 1999

Y1 - 1999

N2 - One of the major obstacles to the development of gene therapy for cancer is our inability to deliver genes to all targets within the body. Thus, effective methodology does not exist to deliver a gene intravenously with the expectation that it will selectively localize within the target tumor, will not localize in other tissues and will be expressed efficiently. While one can take advantage of tissue-specific promoters to activate the gene only in a given target tissue, only a small fraction of the vector will be taken up in the target tissue and expressed. Consequently, since accessible local or regional tumor masses are a major problem in many cancers, there has been a strong emphasis on clinical trials in intratumoral and peritumoral gene delivery.

AB - One of the major obstacles to the development of gene therapy for cancer is our inability to deliver genes to all targets within the body. Thus, effective methodology does not exist to deliver a gene intravenously with the expectation that it will selectively localize within the target tumor, will not localize in other tissues and will be expressed efficiently. While one can take advantage of tissue-specific promoters to activate the gene only in a given target tissue, only a small fraction of the vector will be taken up in the target tissue and expressed. Consequently, since accessible local or regional tumor masses are a major problem in many cancers, there has been a strong emphasis on clinical trials in intratumoral and peritumoral gene delivery.

UR - http://www.scopus.com/inward/record.url?scp=0032844957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032844957&partnerID=8YFLogxK

M3 - Article

C2 - 11713758

AN - SCOPUS:0032844957

VL - 1

SP - 443

EP - 453

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 4

ER -